フィリピン - 英語 - FDA (Food And Drug Administration)

hipra philippines inc.; distributor: hipra philippines inc. - inactivated clostridium perfringens b and € , clostridium novyi a , clostridium septicum a , clostridium chauvoei , clostridium tetani vaccine (vet.) - suspension for injection (im/sc) - formulation: each 2 ml[dose) contains: clostridium perfringens (type b, c and d) b toxoid ->10 iu c. perfringens (type b, c and d) e toxoid-5iu clostridium novyi (type b) e toxoid->5 iu clostridium septicum a toxoid-->5 iu clostridium chauvoei- 100% protection clostridium tetani-->5 iu

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (unii: qsn5xo8zsu) (bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) - unii:qsn5xo8zsu), bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (unii: 8c367iy4ey) (bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) - unii:8c367iy4ey), bordetella pertussis pertactin antigen (formaldehyde inactivated) (unii: i05o535nv6) (bordetella pertussis pertactin antigen (formaldehyde inactivated) - unii:i05o535nv6) - clostridium tetani toxoid antigen (formaldehyde inactivated) 10 [iu] in 0.5 ml - infanrix is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years (prior to the seventh birthday). severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or to any component of infanrix is a contraindication [see description (11)] . because of the uncertainty as to which component of the vaccine might be responsible, no further vaccination with any of these components should be given. alternatively, such individuals may be referred to an allergist for evaluation if immunization with any of these components is being considered. encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including infanrix. progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy, is a contraindication to administration of any pertussis-containing vaccine, including infanrix. pertussis vaccine should not be administered to individuals with these conditions until a treatment regimen has been established and the condition has stabilized. safety and effectiveness of infanrix in infants aged younger than 6 weeks and children aged 7 to 16 years have not been established. infanrix is not approved for use in these age groups.

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - clostridium haemolyticum; clostridium perfringens type b toxoid; clostridium perfringens type c toxoid; clostridium chauvoei whole cell culture; clostridium novyi tybe b toxiod and inactivated cells; clostridium perfringens type d toxoid; clostridium septicum - toxoid; clostridium tetani - toxoid; thiomersal; aluminium (adjuvant) - misc. vaccines or anti sera - clostridium haemolyticum vaccine-toxoid active 21.2 tcp u/ml; clostridium perfringens type b toxoid vaccine-toxoid active 30.6 tcp u/ml; clostridium perfringens type c toxoid vaccine-toxoid active 15.3 tcp u/ml; clostridium chauvoei whole cell culture vaccine-microbial active 30.0 %ferm/ml; clostridium novyi tybe b toxiod and inactivated cells vaccine-toxiod active 5.95 tcp u/ml; clostridium perfringens type d toxoid vaccine-toxoid active 55.3 tcp u/ml; clostridium septicum - toxoid vaccine-toxoid active 6.4 tcp u/ml; clostridium tetani - toxoid vaccine-toxoid active 3.0 lf u/ml; thiomersal mercury other 0.15 mg/ml; aluminium (adjuvant) mineral-aluminium other 0.0 mg/ml - immunotherapy - cattle | lamb | sheep | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ewe | hei - black disease | blackleg | dysentery | enterotoxaemia (pulpy kidney) | haemorrhagic enterotoxaemia | malignant oedema | post parturient gangrene | swelled head | tetanus | tick fever - bovine babesiosis | babesia bigemina | babesia bovis | clostridium perfringens type d | red water | redwater | tetanus vaccination

スペイン - 英語 - HMA (Heads of Medicines Agencies)

ceva salud animal - clostridium chauvoei 90 %, clostridium novyi alpha toxoid 3.5 iu/ml, clostridium perfringens a 1.1 iu/ml, clostridium perfringens type c toxoid 10 iu/ml, clostridium perfringens type d toxoid 5 iu/ml, clostridium septicum 2.5 iu/ml, clostridium sordelli 100 %, clostridium tetani toxoid 2.5 iu/ml - suspension for injection - sheep food - clostridium vaccine

イタリア - 英語 - HMA (Heads of Medicines Agencies)

ceva salud animal - clostridium chauvoei 90 %, clostridium novyi alpha toxoid 3.5 iu/ml, clostridium perfringens a 1.1 iu/ml, clostridium perfringens type c toxoid 10 iu/ml, clostridium perfringens type d toxoid 5 iu/ml, clostridium septicum 2.5 iu/ml, clostridium sordelli 100 %, clostridium tetani toxoid 2.5 iu/ml - suspension for injection - sheep food - clostridium vaccine

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - clostridium perfringens type d toxoid; clostridium tetani - toxoid; corynebacterium pseudotuberculosis - toxoid; thiomersal - parenteral liquid/solution/suspension - clostridium perfringens type d toxoid vaccine-toxoid active 0.0 p; clostridium tetani - toxoid vaccine-toxoid active 0.0 p; corynebacterium pseudotuberculosis - toxoid vaccine-toxoid active 0.0 p; thiomersal mercury other 0.13 g/l - immunotherapy - sheep | ewe | hogget | lamb | ovine | ram | weaner | wether - cheesy gland | enterotoxaemia (pulpy kidney) | tetanus | clostridium perfringens type d | lymphadenitis | lymphangitis | tetanus vaccination

ニュージーランド - 英語 - Ministry for Primary Industries

ceva animal health (nz) limited - clostridium perfringens type d toxoid; clostridium chauvoei toxoid/cells; clostridium septicum toxoid; clostridium novyi type b toxoid/cells; clostridium perfringens type a toxoid; clostridium perfringens type c toxoid; clostridium tetani toxoid - clostridium perfringens type d toxoid 0 vaccine; clostridium chauvoei toxoid/cells 0 vaccine; clostridium septicum toxoid 0 vaccine; clostridium novyi type b toxoid/cells 0 vaccine; clostridium perfringens type a toxoid 0 vaccine; clostridium perfringens type c toxoid 0 vaccine; clostridium tetani toxoid 0 vaccine - vaccine

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

sanofi pasteur inc. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13) - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) 25 [lf] in 0.5 ml - diphtheria and tetanus toxoids adsorbed is a vaccine indicated for active immunization against diphtheria and tetanus. diphtheria and tetanus toxoids adsorbed is approved for use in children from 6 weeks through 6 years of age (prior to 7th birthday). diphtheria and tetanus toxoids and acellular pertussis vaccine (dtap) or a dtap-containing vaccine is recommended for immunization of infants and children 6 weeks through 6 years of age. diphtheria and tetanus toxoids adsorbed should be used in instances where the pertussis vaccine component is contraindicated. diphtheria and tetanus toxoids adsorbed is not to be used for treatment of diphtheria or tetanus infection. a severe allergic reaction (e.g., anaphylaxis) after a previous dose of diphtheria and tetanus toxoids adsorbed or any other diphtheria toxoid or tetanus toxoid-containing vaccine, or any other component of this vaccine is a contraindication to administration of diphtheria and tetanus toxoids adsorbed. [see description (11). ] diphtheria and tetanu

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

deseret biologicals, inc. - clostridium difficile (unii: pjx89v9r6n) (clostridium difficile - unii:pjx89v9r6n) - clostridium difficile 15 [hp_x] in 1 ml - for temporary relief of symptoms related to clostridium difficile which include occasional diarrhea, intestinal cramping and fevers.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to clostridium difficile which include occasional diarrhea, intestinal cramping and fevers.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

deseret biologicals, inc. - clostridium difficile (unii: pjx89v9r6n) (clostridium difficile - unii:pjx89v9r6n) - clostridium difficile 15 [hp_x] in 1 ml - for temporary relief of symptoms related to clostridium difficile which include uncontrollable diarrhea, intestinal cramping and fevers.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to clostridium difficile which include uncontrollable diarrhea, intestinal cramping and fevers.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.